retatrutide triple agonist obesity Severe Trial Shows 30% Weight Loss glp 1 gip triple agonist

Despite their benefits, GLP-1 side effects can include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation

GLP-1 2022(GLP-1GLP-1) GLP-1 2020(1) (2) (3) (202232) () [ TERAHATA / ] Web - DPP-4 SGLT2 GLP-1 GLP-1 GIP/GLP-1 POCT CGMisCGM 21.5 81 2BMIHbA1c BMI 2MASLD SGLT2BNP SDM QA 1996

Diabetologia (2009) 52:199207

This is the drug doing exactly what its supposed to do, but it can feel strange if youre used to thinking about food constantly or eating out of habit rather than hunger

Clinical Applications and Therapeutic Benefits Recent Phase 2 clinical trials demonstrate remarkable efficacy outcomes that position retatrutide as a game-changing therapeutic option

Combination with SGLT2 inhibitors to augment the benefits of this drug class in HFrEF with, for example, the weight-lowering effects of GLP-1 RA could offer a clinically valuable and feasible option addressing the spectrum of abnormalities associated with this HF phenotype